CHF 8.22
(0.24%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -11.83 Million EUR | 10.81% |
2022 | -13.32 Million EUR | -7.76% |
2021 | -12.31 Million EUR | 31.59% |
2020 | -17.99 Million EUR | 13.69% |
2019 | -20.84 Million EUR | -40.99% |
2018 | -14.78 Million EUR | -265.27% |
2017 | -4.04 Million EUR | 73.53% |
2016 | -15.29 Million EUR | 13.13% |
2015 | -17.6 Million EUR | -94.37% |
2014 | -11.18 Million EUR | -17.06% |
2013 | -7.73 Million EUR | -219.98% |
2012 | -2.63 Million EUR | 61.81% |
2011 | -6.34 Million EUR | 70.54% |
2010 | -21.49 Million EUR | 10.57% |
2009 | -24.03 Million EUR | -33.16% |
2008 | -18.04 Million EUR | -33.31% |
2007 | -13.46 Million EUR | 19.19% |
2006 | -16.72 Million EUR | -11.12% |
2005 | -15.07 Million EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | -7.58 Million EUR | 0.0% |
2023 Q2 | -4.2 Million EUR | 0.0% |
2023 FY | - EUR | 10.81% |
2023 Q4 | -7.28 Million EUR | 0.0% |
2022 FY | - EUR | -7.76% |
2022 Q2 | -6.35 Million EUR | 0.0% |
2022 Q4 | -6.91 Million EUR | 0.0% |
2021 Q2 | -7.78 Million EUR | 0.0% |
2021 Q4 | -4.52 Million EUR | 0.0% |
2021 FY | - EUR | 31.59% |
2020 FY | - EUR | 13.69% |
2020 Q4 | -8.13 Million EUR | 0.0% |
2020 Q2 | -9.85 Million EUR | 0.0% |
2019 Q4 | -6.51 Million EUR | 0.0% |
2019 FY | - EUR | -40.99% |
2019 Q2 | -14.33 Million EUR | 0.0% |
2018 Q2 | -7.5 Million EUR | 0.0% |
2018 Q4 | -7.28 Million EUR | 0.0% |
2018 FY | - EUR | -265.27% |
2017 Q2 | 2.35 Million EUR | 0.0% |
2017 FY | - EUR | 73.53% |
2017 Q4 | -6.4 Million EUR | 0.0% |
2016 Q2 | -8.86 Million EUR | 0.0% |
2016 FY | - EUR | 13.13% |
2016 Q4 | -6.43 Million EUR | 0.0% |
2015 FY | - EUR | -94.37% |
2015 Q2 | -6.82 Million EUR | 0.0% |
2015 Q4 | -10.77 Million EUR | 0.0% |
2014 Q4 | -4.3 Million EUR | 0.0% |
2014 FY | - EUR | -17.06% |
2014 Q2 | -4.74 Million EUR | 0.0% |
2013 Q4 | -3.26 Million EUR | -70.08% |
2013 FY | - EUR | -219.98% |
2013 Q3 | -1.91 Million EUR | 19.69% |
2013 Q2 | -2.38 Million EUR | 0.0% |
2012 Q1 | -604.5 Thousand EUR | 0.0% |
2012 Q2 | -604.5 Thousand EUR | 0.0% |
2012 FY | - EUR | 61.81% |
2012 Q3 | -604.5 Thousand EUR | 0.0% |
2012 Q4 | -1.91 Million EUR | -217.37% |
2011 Q3 | -1.58 Million EUR | 0.0% |
2011 Q1 | -1.58 Million EUR | 0.0% |
2011 Q2 | -1.58 Million EUR | 0.0% |
2011 FY | - EUR | 70.54% |
2011 Q4 | -604.5 Thousand EUR | 61.88% |
2010 Q3 | -5.38 Million EUR | 0.0% |
2010 FY | - EUR | 10.57% |
2010 Q1 | -5.38 Million EUR | 0.0% |
2010 Q4 | -1.58 Million EUR | 70.53% |
2010 Q2 | -5.38 Million EUR | 0.0% |
2009 Q4 | -5.38 Million EUR | 9.67% |
2009 FY | - EUR | -33.16% |
2009 Q3 | -5.95 Million EUR | 0.0% |
2009 Q2 | -5.95 Million EUR | 0.0% |
2009 Q1 | -5.95 Million EUR | 0.0% |
2008 Q2 | -4.02 Million EUR | 0.0% |
2008 Q1 | -4.02 Million EUR | 0.0% |
2008 FY | - EUR | -33.31% |
2008 Q4 | -5.95 Million EUR | -48.13% |
2008 Q3 | -4.02 Million EUR | 0.0% |
2007 Q3 | -2.71 Million EUR | 0.0% |
2007 Q2 | -2.71 Million EUR | 0.0% |
2007 Q1 | -2.71 Million EUR | 0.0% |
2007 FY | - EUR | 19.19% |
2007 Q4 | -4.02 Million EUR | -47.91% |
2006 FY | - EUR | -11.12% |
2006 Q1 | -4.1 Million EUR | 0.0% |
2006 Q3 | -4.1 Million EUR | 0.0% |
2006 Q2 | -4.1 Million EUR | 0.0% |
2006 Q4 | -2.71 Million EUR | 33.69% |
2005 Q3 | -3.72 Million EUR | 0.0% |
2005 Q1 | -3.72 Million EUR | 0.0% |
2005 Q2 | -3.72 Million EUR | 0.0% |
2005 FY | - EUR | 0.0% |
2005 Q4 | -4.1 Million EUR | -9.93% |
2004 Q4 | -3.72 Million EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Relief Therapeutics Holding AG | -108.2 Million CHF | 89.066% |
Tecan Group AG | 205.57 Million CHF | 105.755% |
Santhera Pharmaceuticals Holding AG | 79.17 Million CHF | 114.943% |
Basilea Pharmaceutica AG | 29.49 Million CHF | 140.112% |
Bachem Holding AG | 163.27 Million CHF | 107.246% |
Siegfried Holding AG | 241.21 Million CHF | 104.905% |
Molecular Partners AG | -59.51 Million CHF | 80.121% |